OptionsHouse

Options Trading News

November 27, 2012  Tue 7:23 AM CT

ACAD: SEE CHART GET CHAIN FIND STRATEGIES

Primary and Secondary Endpoints Are Met

Acadia Phaemaceuticals announced successful top-line results for the Phase III trial of its Pimavanserin drug for patients with Parkinson’s disease psychosis. The compound met the primary endpoint by demonstrating highly significant antipsychotic efficacy using a nine-item scale. It also met a secondary endpoint for motoric tolerability. ACAD is up 160 percent before the bell on my tradeMONSTER platform!

Ralcorp Accepts ConAgra Takeover Offer

Ralcorp agreed to be purchased by ConAgra for $90 a share in cash. That's a nice premium for RAH, which closed at $70.23 yesterday, and the stock is up almost 27 percent in early trading.

Las Vegas Sands Rallies on Special Dividend

Las Vegas Sands announced that its board approved a special dividend of $2.75 a share in cash. LVS climbs more than 4 percent in the premarket.

Share this article with your friends


Related Stories

ACAD

Acadia Pharma faces downside position

April 25, 2016

The drug developer is up 49 percent in the last month but is drawing bearish option activity ahead of its expected earnings report in early May.

OptionsHouse

Premium Services

Education & Strategy

Market Level Making You Nervous, Huh? Part 3

In last week's article, we discussed how important the extra cash you save by using the Stock Replacement Strategy over buying the actual stock is! That extra cash in our account instead of being unnecessarily tied up in a stock position allows us to buy the puts we would need to protect our downside in the case of a major sell-off.

View more education articles »